Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Safety Risks for NSAIDs, and More Products
February 1, 2021
- Govt Giving Advice to Fujifilm after Shelving Decision on Avigan
February 1, 2021
- PAFSC OKs Seikagaku’s Osteoarthritis Med for Use Excluding Ankle Joints, Bayer’s Larotrectinib Too
February 1, 2021
- Japan Enacts 3rd Extra Budget, 4.4 Trillion Yen to Stem Spread of COVID-19
January 29, 2021
- MHLW Wants to Encourage Non-Monitoring Facilities to Report Inappropriate Drug Promotion
January 29, 2021
- Fujimoto’s Thaled Now in Line for Approval for POEMS Syndrome
January 28, 2021
- MHLW Official Urges Pref. Govts to Implement Thorough Inspection, Guidance for Drug Makers after Kobayashi Kako Fiasco
January 28, 2021
- LDP COVID-19 Vaccine Project Team to Compile Proposal before Rollout
January 27, 2021
- Label Revisions Ordered for Pomalyst, MabCampath, and More
January 27, 2021
- Kobayashi Kako Might Face 116-Day Biz Suspension over Drug Mix-Up
January 27, 2021
- Japan to Set Up Real-Time Tracking System for COVID-19 Vaccination: Kono
January 26, 2021
- Kobayashi Kako Notified of Record Biz Suspension of 110-Plus Days over Drug Mix-Up
January 26, 2021
- MHLW Approves Sakigake-Designated HAE Treatment, Lilly’s Migraine Med, Takeda’s Alunbrig, Ono’s Cachexia Drug, and More
January 25, 2021
- Japan Preps for COVID-19 Vaccine Rollout for HCPs by Late February: Minister
January 25, 2021
- Japan Govt Starts COVID-19 Vaccine Website, Plans Air/Land Shipments by Logistics Firms for Pfizer Shots
January 25, 2021
- MHLW Publishes Members’ Names of DPO; Disclosure of Minutes Expected as Early as Summer
January 25, 2021
- LDP Medical Legislator Group Proposes Stockpiling of EpiPen at COVID-19 Vaccination Centers
January 25, 2021
- MHLW Plans 4-Week Follow-Up Study on Early COVID-19 Vaccine Recipients
January 21, 2021
- Kobayashi Kako Submits Report on Drug Mix-Up, Could Face Administrative Penalty in 1st Half of February
January 21, 2021
- Japan, Pfizer Finalize COVID-19 Vaccine Deal, Agree on Supply of 144 Million Doses
January 21, 2021
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…